F082 - Rheumatology for the Dermatologist: Evaluating the Rheumatology Patient in the Dermatology Clinic
Saturday, March 2; 3:30 PM - 5:30 PM
Following this course, the attendee should be able to:
- Define the relationship between cutaneous and systemic lupus, describe dermatomyositis as defined by autoantibody profiles, distinguish inflammatory and non-inflammatory arthritis.
- Appropriately order and interpret autoimmune serologic testing.
- Develop a helpful review of systems to approach systemic rheumatologic disease.
We will review the relationship between cutaneous lupus subsets and systemic lupus as well as current understanding of prognostic implications of CLE with regard to systemic disease. We will review dermatomyositis clinical findings (skin and systemic) as they relate to autoantibody profiles. We will review appropriate rheumatology review of systems and approach to inflammatory arthritis for the dermatologist. Other topics will include brief review of systemic sclerosis screening and monitoring.
- Merola, Joseph, MD, MSc: AbbVie – C(H); Amgen – A(H); Celgene Corporation – C(H); Dermavant Sciences – I(Fees); Eli Lilly and Company – C(Fees); Janssen Pharmaceuticals, Inc – C(H); LEO Laboratories Ltd (LEO Pharma) – I(Fees); Merck – C(H); Novartis – C(H); Pfizer Inc. – I(Fees); Sanofi/Regeneron – C(H); UCB – C(H);